Carfilzomib: a novel second-generation proteasome inhibitor
about
One-shot NMR analysis of microbial secretions identifies highly potent proteasome inhibitorNovel therapeutics in multiple myeloma.The 26S proteasome complex: an attractive target for cancer therapySpecificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human CellsPeripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.Thrombotic microangiopathy during carfilzomib use: case series in Singapore.Targeted inhibition of the COP9 signalosome for treatment of cancerImpact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR studyBortezomib for previously untreated multiple myeloma.New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies.Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value.Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.Small molecules as pro-apoptotic anticancer agents.Multiple myeloma maintenance therapy: a review of the pharmacologic treatment.Label-free Proteomic Analysis of Exosomes Derived from Inducible Hepatitis B Virus-Replicating HepAD38 Cell Line.Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.Posttranslational Regulation of Organic Anion Transporters by Ubiquitination: Known and Novel.Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.Emerging challenges in the design of selective substrates, inhibitors and activity-based probes for indistinguishable proteases.Mechanisms of tolvaptan-induced toxicity in HepG2 cells.Proteasom-Inhibitoren
P2860
Q27674685-F29689A0-7ADE-45E6-B128-BC6B55EE3C69Q34637538-6D6B4EFD-5C02-484B-BBEB-D7595BF3E4E7Q35624079-E3BC3463-B58C-4FAE-850E-82C0DE695620Q36098363-A924B6C8-1C0F-4436-80A6-E8E62654E1EBQ36344699-3B177A14-5B6F-4F7E-B843-6B3337355CC2Q37132187-45F614C5-2E7C-4D71-B87C-82D5DCE3E66DQ37271015-BF164CEB-67B7-459B-BDC8-F6A4725191A0Q37364323-07C20ABB-F73D-43A2-8AEE-ED2771163AB6Q37570630-C8847192-E809-4367-9C4E-CFF13999E9F6Q37908155-469F81FC-DF0F-476A-BB08-DABA6EFB6D65Q38002469-FA9B9280-B35F-4F93-84D7-0A864411A2B6Q38020248-B49AFB4D-2D4D-4C06-BC8E-BA684015F437Q38042295-00793063-3C22-4554-8689-E15641BB56ECQ38162939-6954AF6B-A099-43DA-93F5-398329110E09Q38176293-96AC52B5-74F3-4161-BA0E-A00C61AD1B53Q38714573-E836DC81-4845-4880-803D-8FEA3432E675Q38725959-ADDD2D9A-B441-4B28-9A5E-D6443224A749Q38862493-AB8529D3-1B38-4CA4-95CA-534566134C7DQ38989789-A4EFB7C1-FD98-41E7-BADD-B075AFD2F518Q39067283-FC8C5E89-0498-4403-B3AE-45590E64E56EQ55061705-60DF7683-68B0-4184-9D73-5D775B03E5A7Q58854984-D9335890-A4D3-478F-9618-ECF4DDF9B8AE
P2860
Carfilzomib: a novel second-generation proteasome inhibitor
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Carfilzomib: a novel second-generation proteasome inhibitor
@ast
Carfilzomib: a novel second-generation proteasome inhibitor
@en
type
label
Carfilzomib: a novel second-generation proteasome inhibitor
@ast
Carfilzomib: a novel second-generation proteasome inhibitor
@en
prefLabel
Carfilzomib: a novel second-generation proteasome inhibitor
@ast
Carfilzomib: a novel second-generation proteasome inhibitor
@en
P2860
P356
P1433
P1476
Carfilzomib: a novel second-generation proteasome inhibitor
@en
P2093
A Keith Stewart
Meaghan L Khan
P2860
P304
P356
10.2217/FON.11.42
P407
P577
2011-05-01T00:00:00Z